Vilobelimab Shows Signs of Efficacy in Phase 3 Trial for Rare Skin Disorder

InflaRx is reviving hopes for vilobelimab, a drug for rare skin disorder pyoderma gangrenosum (PG), after new analyses showed signs of efficacy in a Phase 3 trial it had previously halted. The company will meet with the FDA to discuss a potential path forward and considers partnering with a company to further develop vilobelimab. Post-hoc analyses suggest a positive trend in favor of vilobelimab, with signals indicating a potentially consistent treatment effect.